CK Life Sciences Int'l. (Holdings) Crecimiento futuro
Future controles de criterios 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for CK Life Sciences Int'l. (Holdings).
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 41.8% |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | None |
| Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
No hay actualizaciones
Recent updates
CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Oct 04
There's No Escaping CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Muted Revenues Despite A 32% Share Price Rise
May 03CK Life Sciences Int'l. (Holdings)'s (HKG:775) Anemic Earnings Might Be Worse Than You Think
Apr 25CK Life Sciences Int'l. (Holdings) (HKG:775) Use Of Debt Could Be Considered Risky
Mar 26Here's Why CK Life Sciences Int'l. (Holdings) (HKG:775) Can Manage Its Debt Responsibly
Sep 27Does CK Life Sciences Int'l. (Holdings) (HKG:775) Have A Healthy Balance Sheet?
Sep 16Estimating The Intrinsic Value Of CK Life Sciences Int'l., (Holdings) Inc. (HKG:775)
Aug 21These 4 Measures Indicate That CK Life Sciences Int'l. (Holdings) (HKG:775) Is Using Debt Extensively
Apr 14CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) Delivered A Weaker ROE Than Its Industry
Mar 18If You Had Bought CK Life Sciences Int'l. (Holdings) (HKG:775) Shares Five Years Ago You'd Have Earned 45% Returns
Feb 01
What Kind Of Shareholders Hold The Majority In CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Shares?
Jan 04CK Life Sciences Int'l. (Holdings) (HKG:775) Has A Somewhat Strained Balance Sheet
Dec 09We Wouldn't Rely On CK Life Sciences Int'l. (Holdings)'s (HKG:775) Statutory Earnings As A Guide
Nov 18En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como CK Life Sciences Int'l. (Holdings) no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.
Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.
Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 6/30/2024 | 5,379 | -19 | 418 | 579 | N/A |
| 3/31/2024 | 5,351 | -1 | 385 | 547 | N/A |
| 12/31/2023 | 5,323 | 17 | 353 | 514 | N/A |
| 9/30/2023 | 5,318 | 61 | 191 | 372 | N/A |
| 6/30/2023 | 5,314 | 104 | 100 | 230 | N/A |
| 3/31/2023 | 5,295 | 118 | 137 | 297 | N/A |
| 12/31/2022 | 5,276 | 132 | 175 | 364 | N/A |
| 9/30/2022 | 5,290 | 130 | 302 | 486 | N/A |
| 6/30/2022 | 5,305 | 128 | 430 | 608 | N/A |
| 3/31/2022 | 5,353 | 145 | 318 | 516 | N/A |
| 12/31/2021 | 5,402 | 163 | 206 | 424 | N/A |
| 9/30/2021 | 5,302 | 150 | 107 | 429 | N/A |
| 6/30/2021 | 5,201 | 138 | 7 | 435 | N/A |
| 3/31/2021 | 5,072 | 132 | 79 | 483 | N/A |
| 12/31/2020 | 4,943 | 125 | 151 | 531 | N/A |
| 9/30/2020 | 4,846 | 112 | 139 | 433 | N/A |
| 6/30/2020 | 4,750 | 98 | 128 | 335 | N/A |
| 3/31/2020 | 4,859 | 140 | 155 | 357 | N/A |
| 12/31/2019 | 4,967 | 182 | 181 | 379 | N/A |
| 9/30/2019 | 5,128 | 223 | 90 | 337 | N/A |
| 6/30/2019 | 5,288 | 263 | -1 | 295 | N/A |
| 3/31/2019 | 5,261 | 263 | -29 | 263 | N/A |
| 12/31/2018 | 5,233 | 263 | -57 | 231 | N/A |
| 9/30/2018 | 5,077 | 261 | N/A | N/A | N/A |
| 6/30/2018 | 4,920 | 259 | 165 | 237 | N/A |
| 3/31/2018 | 4,807 | 259 | N/A | 186 | N/A |
| 12/31/2017 | 4,693 | 258 | N/A | 135 | N/A |
| 9/30/2017 | 4,674 | 247 | N/A | N/A | N/A |
| 6/30/2017 | 4,655 | 236 | N/A | 352 | N/A |
| 3/31/2017 | 4,762 | 244 | N/A | 396 | N/A |
| 12/31/2016 | 4,869 | 253 | N/A | 439 | N/A |
| 9/30/2016 | 4,933 | 240 | N/A | N/A | N/A |
| 6/30/2016 | 4,998 | 228 | N/A | 314 | N/A |
| 3/31/2016 | 4,959 | 223 | N/A | 309 | N/A |
| 12/31/2015 | 4,919 | 219 | N/A | 304 | N/A |
| 9/30/2015 | 4,953 | 257 | N/A | N/A | N/A |
| 6/30/2015 | 4,987 | 296 | N/A | 263 | N/A |
| 3/31/2015 | 4,970 | 280 | N/A | 294 | N/A |
| 12/31/2014 | 4,954 | 264 | N/A | 325 | N/A |
| 9/30/2014 | 4,930 | 250 | N/A | 312 | N/A |
| 6/30/2014 | 4,907 | 236 | N/A | 300 | N/A |
| 3/31/2014 | 4,939 | 232 | N/A | 283 | N/A |
| 12/31/2013 | 4,971 | 229 | N/A | 267 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Insufficient data to determine if 775's forecast earnings growth is above the savings rate (2.3%).
Beneficios vs. Mercado: Insufficient data to determine if 775's earnings are forecast to grow faster than the Hong Kong market
Beneficios de alto crecimiento: Insufficient data to determine if 775's earnings are expected to grow significantly over the next 3 years.
Ingresos vs. Mercado: Insufficient data to determine if 775's revenue is forecast to grow faster than the Hong Kong market.
Ingresos de alto crecimiento: Insufficient data to determine if 775's revenue is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if 775's Return on Equity is forecast to be high in 3 years time